» Articles » PMID: 27194472

Sodium Tanshinone IIA Sulfonate Inhibits Hypoxia-induced Enhancement of SOCE in Pulmonary Arterial Smooth Muscle Cells Via the PKG-PPAR-γ Signaling Axis

Overview
Specialties Cell Biology
Physiology
Date 2016 May 20
PMID 27194472
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Our laboratory previously showed that sodium tanshinone IIA sulfonate (STS) inhibited store-operated Ca(2+) entry (SOCE) through store-operated Ca(2+) channels (SOCC) via downregulating the expression of transient receptor potential canonical proteins (TRPC), which contribute to the formation of SOCC (Wang J, Jiang Q, Wan L, Yang K, Zhang Y, Chen Y, Wang E, Lai N, Zhao L, Jiang H, Sun Y, Zhong N, Ran P, Lu W. Am J Respir Cell Mol Biol 48: 125-134, 2013). The detailed molecular mechanisms by which STS inhibits SOCE and downregulates TRPC, however, remain largely unknown. We have previously shown that, under hypoxic conditions, inhibition of protein kinase G (PKG) and peroxisome proliferator-activated receptor-γ (PPAR-γ) signaling axis results in the upregulation of TRPC (Wang J, Yang K, Xu L, Zhang Y, Lai N, Jiang H, Zhang Y, Zhong N, Ran P, Lu W. Am J Respir Cell Mol Biol 49: 231-240, 2013). This suggests that strategies targeting the restoration of this signaling pathway may be an effective treatment strategy for pulmonary hypertension. In this study, our results demonstrated that STS treatment can effectively prevent the hypoxia-mediated inhibition of the PKG-PPAR-γ signaling axis in rat distal pulmonary arterial smooth muscle cells (PASMCs) and distal pulmonary arteries. These effects of STS treatment were blocked by pharmacological inhibition or specific small interfering RNA knockdown of either PKG or PPAR-γ. Moreover, targeted PPAR-γ agonist markedly enhanced the beneficial effects of STS. These results comprehensively suggest that STS treatment can prevent hypoxia-mediated increases in intracellular calcium homeostasis and cell proliferation, by targeting and restoring the hypoxia-inhibited PKG-PPAR-γ signaling pathway in PASMCs.

Citing Articles

Progress of tanshinone IIA against respiratory diseases: therapeutic targets and potential mechanisms.

Ding Z, Deng Y, Luo H, Liu C, Yang M, Xue H Front Pharmacol. 2025; 16:1505672.

PMID: 40066338 PMC: 11891354. DOI: 10.3389/fphar.2025.1505672.


The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions.

Kounatidis D, Vallianou N, Rebelos E, Kouveletsou M, Kontrafouri P, Eleftheriadou I Curr Obes Rep. 2025; 14(1):19.

PMID: 39934485 DOI: 10.1007/s13679-025-00612-4.


A systematic review and meta-analysis on sodium tanshinone IIA sulfonate injection for the adjunctive therapy of pulmonary heart disease.

Shao H, Yu F, Xu D, Fang C, Tong R, Zhao L BMC Complement Med Ther. 2024; 24(1):151.

PMID: 38580972 PMC: 10996144. DOI: 10.1186/s12906-024-04434-0.


Unleashing the Potential of Nrf2: A Novel Therapeutic Target for Pulmonary Vascular Remodeling.

Fang Q, Bai Y, Hu S, Ding J, Liu L, Dai M Antioxidants (Basel). 2023; 12(11).

PMID: 38001831 PMC: 10669195. DOI: 10.3390/antiox12111978.


Natural Products for the Treatment of Pulmonary Hypertension: Mechanism, Progress, and Future Opportunities.

Zeng Z, Wang X, Cui L, Wang H, Guo J, Chen Y Curr Issues Mol Biol. 2023; 45(3):2351-2371.

PMID: 36975522 PMC: 10047369. DOI: 10.3390/cimb45030152.


References
1.
Wang J, Lu W, Wang W, Zhang N, Wu H, Liu C . Promising therapeutic effects of sodium tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients. J Thorac Dis. 2013; 5(2):169-72. PMC: 3621926. DOI: 10.3978/j.issn.2072-1439.2013.02.04. View

2.
Wang J, Shimoda L, Sylvester J . Capacitative calcium entry and TRPC channel proteins are expressed in rat distal pulmonary arterial smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2003; 286(4):L848-58. DOI: 10.1152/ajplung.00319.2003. View

3.
Crossno Jr J, Garat C, Reusch J, Morris K, Dempsey E, McMurtry I . Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol. 2006; 292(4):L885-97. DOI: 10.1152/ajplung.00258.2006. View

4.
Thenappan T, Glassner C, Gomberg-Maitland M . Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension. Chest. 2011; 141(3):642-650. DOI: 10.1378/chest.11-0969. View

5.
Michalik L, Auwerx J, Berger J, Chatterjee V, Glass C, Gonzalez F . International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 2006; 58(4):726-41. DOI: 10.1124/pr.58.4.5. View